Table 1 Basic clinicopathological characteristics of patients and their treatment.
Variable | Value: median or number (N = 179) |
|---|---|
Age | 53 (19–79, IQR: 20.5) |
Sex | |
Male | 73 (40.8%) |
Female | 106 (59.2%) |
IDH status | |
Absent | 80 (44.7%) |
Present | 99 (55.3%) |
1p/19q codeletion | |
Absent | 139 (77.6%) |
Present | 40 (22.3%) |
MGMT promoter methylation in glioblastoma | |
Unmethylated | 30 (16.8%) |
Methylated | 50 (27.9%) |
Glioma grade and subtype | |
WHO G2 | |
Astrocytoma | 25 (14.0%) |
Oligodendroglioma | 20 (11.2%) |
WHO G3 | |
Astrocytoma | 31 (17.3%) |
Oligodendroglioma | 20 (11.2%) |
WHO G4 | |
Glioblastoma | 80 (44.7%) |
Astrocytoma | 3 (1.7%) |
Chemotherapy | |
No | 45 (25.1%) |
Yes | 134 (74.9%) |
Steroid use at the beginning of radio(chemo)therapy | |
No | 141 (78.8%) |
Yes | 38 (21.2%) |
Radiotherapy-related factors | |
Radiotherapy technique | |
IMRT | 100 (55.9%) |
VMAT | 79 (44.1%) |
Fractionation scheme | |
Conventional | 83.20% |
Hypofractionated | 16.80% |
Total dose [Gy] | 60 (32.50–80) |
Fraction dose [Gy] | 2.00 (1.80–2.80) |
Number of fractions | 30 (13–33) |
Total EQD2 dose [Gy] | 60 (35.75–88) |
Volumetric and dosimetric variables | |
CTV (mL) | 175.3 (11.2–586.9) |
PTV (mL) | 264.4 (52.4–777.7) |
Brain volume (mL) | 1419.0 (1046.9–1788.6) |
Brain – PTV (mL) | 1144.9 (650.5–1694.4) |
V5Gy (%) | 83.6 (36.8–100.0) |
V10Gy (%) | 74.4 (28.5–99.6) |
V15Gy (%) | 64.5 (23.3–99.3) |
V20Gy (%) | 55.9 (18.1–97.2) |
V25Gy (%) | 48.6 (14.0–94.6) |
V30Gy (%) | 41.7 (11.5–91.9) |
V40Gy (%) | 32.7 (7.7–81.5) |
V50Gy (%) | 26.1 (0.0–72.5) |
Mean dose (Gy) | 25.1 (6.8–42.3) |
Median dose (Gy) | 19.37 (2.1–54.9) |
Whole brain minimal dose (Gy) | 0.64 (0.04–4.8) |
